BACKGROUND: Glycogen storage disease type I (GSD I) causes severe hypoglycemia during periods of fasting since both glycogenolysis and gluconeogenesis are impaired. Primary treatment in North America consists of cornstarch therapy every 3-4 h. Waxy maize extended release cornstarch was introduced for maintaining overnight glucose concentrations, but no studies have assessed long-term safety and efficacy of the product. OBJECTIVE: To demonstrate the safety and efficacy of modified cornstarch in GSD I. DESIGN: An open-label overnight trial of extended release cornstarch was performed. Subjects with a successful trial (optimal metabolic control 2 or more hours longer than with traditional cornstarch) were given the option of continuing into the chronic observational phase. Subjects were assessed biochemically at baseline and after 12 months. RESULTS: Of the 106 subjects (93 GSD Ia/13 GSD Ib), efficacy was demonstrated in 82 patients (88%) with GSD Ia and 10 patients (77%) with GSD Ib. The success rate for extending fasting was 95% for females and 78% for males. Of the patients who entered the longitudinal phase, long-term data are available for 44 subjects. Mean duration of fasting on traditional cornstarch prior to study for the cohort was 4.1 and 7.8 h on the extended release cornstarch (P < 0.001). All laboratory markers of metabolic control have remained stable in the chronically treated patients. CONCLUSION: Extended release cornstarch appears to improve the quality of life of patients with GSD I without sacrificing metabolic control. Avoiding the overnight dose of cornstarch should enhance safety in this population.
BACKGROUND: Glycogen storage disease type I (GSD I) causes severe hypoglycemia during periods of fasting since both glycogenolysis and gluconeogenesis are impaired. Primary treatment in North America consists of cornstarch therapy every 3-4 h. Waxy maize extended release cornstarch was introduced for maintaining overnight glucose concentrations, but no studies have assessed long-term safety and efficacy of the product. OBJECTIVE: To demonstrate the safety and efficacy of modified cornstarch in GSD I. DESIGN: An open-label overnight trial of extended release cornstarch was performed. Subjects with a successful trial (optimal metabolic control 2 or more hours longer than with traditional cornstarch) were given the option of continuing into the chronic observational phase. Subjects were assessed biochemically at baseline and after 12 months. RESULTS: Of the 106 subjects (93 GSD Ia/13 GSD Ib), efficacy was demonstrated in 82 patients (88%) with GSD Ia and 10 patients (77%) with GSD Ib. The success rate for extending fasting was 95% for females and 78% for males. Of the patients who entered the longitudinal phase, long-term data are available for 44 subjects. Mean duration of fasting on traditional cornstarch prior to study for the cohort was 4.1 and 7.8 h on the extended release cornstarch (P < 0.001). All laboratory markers of metabolic control have remained stable in the chronically treated patients. CONCLUSION: Extended release cornstarch appears to improve the quality of life of patients with GSD I without sacrificing metabolic control. Avoiding the overnight dose of cornstarch should enhance safety in this population.
Authors: K Bhattacharya; R C Orton; X Qi; H Mundy; D W Morley; M P Champion; S Eaton; R F Tester; P J Lee Journal: J Inherit Metab Dis Date: 2007-05-19 Impact factor: 4.982
Authors: Kaustuv Bhattacharya; Helen Mundy; Maggie F Lilburn; Michael P Champion; David W Morley; François Maillot Journal: Orphanet J Rare Dis Date: 2015-02-15 Impact factor: 4.123
Authors: Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein Journal: J Inherit Metab Dis Date: 2017-06-13 Impact factor: 4.982
Authors: Katalin M Ross; Iris A Ferrecchia; Kathryn R Dahlberg; Monika Dambska; Patrick T Ryan; David A Weinstein Journal: Adv Nutr Date: 2020-03-01 Impact factor: 8.701
Authors: María M Adeva-Andany; Manuel González-Lucán; Cristóbal Donapetry-García; Carlos Fernández-Fernández; Eva Ameneiros-Rodríguez Journal: BBA Clin Date: 2016-02-27
Authors: Ali Saeed; Joanne A Hoogerland; Hanna Wessel; Janette Heegsma; Terry G J Derks; Eveline van der Veer; Gilles Mithieux; Fabienne Rajas; Maaike H Oosterveer; Klaas Nico Faber Journal: Hum Mol Genet Date: 2020-01-15 Impact factor: 6.150
Authors: Terry G J Derks; David F Rodriguez-Buritica; Ayesha Ahmad; Foekje de Boer; María L Couce; Sarah C Grünert; Philippe Labrune; Nerea López Maldonado; Carolina Fischinger Moura de Souza; Rebecca Riba-Wolman; Alessandro Rossi; Heather Saavedra; Rupal Naik Gupta; Vassili Valayannopoulos; John Mitchell Journal: Nutrients Date: 2021-10-27 Impact factor: 5.717